Brii Biosciences (HKSE:02137) Equity-to-Asset : 0.98 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Brii Biosciences Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Brii Biosciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$3,411.54 Mil. Brii Biosciences's Total Assets for the quarter that ended in Dec. 2023 was HK$3,498.18 Mil.

The historical rank and industry rank for Brii Biosciences's Equity-to-Asset or its related term are showing as below:

HKSE:02137' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.37 Med: 0.93 Max: 0.98
Current: 0.98

During the past 5 years, the highest Equity to Asset Ratio of Brii Biosciences was 0.98. The lowest was -1.37. And the median was 0.93.

HKSE:02137's Equity-to-Asset is ranked better than
99.29% of 1559 companies
in the Biotechnology industry
Industry Median: 0.67 vs HKSE:02137: 0.98

Brii Biosciences Equity-to-Asset Historical Data

The historical data trend for Brii Biosciences's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brii Biosciences Equity-to-Asset Chart

Brii Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

-0.59

-1.37

0.93

0.94

0.98

Brii Biosciences Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial				0.93	0.92	0.94	0.98	0.98

Competitive Comparison of Brii Biosciences's Equity-to-Asset

For the Biotechnology subindustry, Brii Biosciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Brii Biosciences's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Brii Biosciences's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Brii Biosciences's Equity-to-Asset falls into.

Brii Biosciences Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Brii Biosciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	3411.54	/	3498.179
	=	0.98

Brii Biosciences's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	3411.54	/	3498.179
	=

Brii Biosciences (HKSE:02137) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Brii Biosciences Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Brii Biosciences's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Brii Biosciences (HKSE:02137) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brii Biosciences Ltd (HKSE:02137) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

BRIBF:USA 7SS:Germany

Address

No. 1 North Yongtaizhuang Road, 3rd Floor, Building 7, Zhongguancun Dongsheng, International Science Park, Haidian District, Beijing, CHN, 100192

Website

https://www.briibio.com

Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed towards developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as the CNS diseases, which have public health burdens in China and worldwide. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.

Executives

Hong Zhi	2101 Beneficial owner
Xyxy Holdings Ltd.	2201 Interest of corporation controlled by you
Booming Passion Limited	2101 Beneficial owner
Boyu Capital Fund Iii, L.p.	2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, L.p.	2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, Ltd	2201 Interest of corporation controlled by you
Tong Xiaomeng	2201 Interest of corporation controlled by you
Boyu Group, Llc	2201 Interest of corporation controlled by you
Boyu Capital Group Holdings Ltd	2201 Interest of corporation controlled by you
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Invesco Advisers, Inc.	2102 Investment manager
Ma Yun	2201 Interest of corporation controlled by you
Yunfeng Investment Iii, Ltd.	2201 Interest of corporation controlled by you
Yunfeng Fund Iii, L.p.	2201 Interest of corporation controlled by you
Yf Bright Insight Limited	2101 Beneficial owner

Brii Biosciences (HKSE:02137) Headlines

No Headlines